Transgenomic Inc.
Provider of research tools closes announced private placement of common stock
Published in Genetics and Environmental Business Week, December 8th, 2005
The transaction was priced at $1.01 per share. Net proceeds from the sale were used to repay the company's indebtedness with Laurus Master Fund, Ltd. of approximately $8.6 million, with the remainder retained for general working capital needs.
The offering and sale of the shares and warrants to these institutional investors was exempt from the registration requirements of the Securities Act of 1933....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Cepheid
Genetic assessment company reports third-quarter 2005 results - Human Genome Sciences, Inc.
Genomics firm calls for all remaining outstanding subordinated notes due 2007 - Targeted Genetics Corporation
Biotechnology company reports third quarter net loss of $5.7 million - ZymoGenetics, Inc.
Company developing therapeutic proteins reports net loss of $20.4 million - Aarhus University Hospital
Mutations in arginine vasopressin gene indicate genotype-phenotype correlation in FNDI - Affymetrix, Inc.
Partnership aims to discover, validate gene expression signatures for common childhood cancers - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
